Il y a quelques jours, passait sur France 3 un reportage sur les dangers des GSM et des antennes relais, il s’intitule « mauvaises ondes », et vous pouvez le télécharger (illégalement ! ) ici :
Il s’agit d’une étape extrêmement importante dans le dossier « téléphonie mobile et santé ».
Pour la première fois, la reconnaissance de la cancéroginicité potentielle est reconnue et ceci au niveau le plus élevé des agences de santé puisqu’il s’agit de l’OMS. Une fois le risque reconnu, le problème devient essentiellement politique.
Des mesures doivent être prises immédiatement tant au niveau international qu’au niveau des Etats pour le réduire. Pour cela, il est nécessaire :
de réduire les niveaux expositions tant pour les utilisateurs de portables que pour les riverains d’antennes ;
il faut réduire les sources d’exposition, en rappelant que les connexions filaires doivent être privilégiées chaque fois que cela est possible (utilisation du téléphone filaire à la maison ou sur les lieux de travail, connexion internet filaire avec facilité de désactivation du WiFi sur les box… ) ;
il faut informer largement sur les risques et tout particulièrement sur les risques pour les enfants ; il faut interdire les produits spécifiquement destinés aux enfants.
A partir d’aujourd’hui, plus personne ne pourra dire « le risque n’existe pas » et chacun à son niveau - politiques, opérateurs, employeurs, utilisateurs, parents,… - devra en tenir compte
Le communiqué de l'OMS :
IARC CLASSIFIES RADIOFREQUENCY ELECTROMAGNETIC FIELDS AS
POSSIBLY CARCINOGENIC TO HUMANS
Lyon, France, May 31, 2011 -- The WHO/International Agency for Research on Cancer (IARC) has
classified radiofrequency electromagnetic fields as possibly carcinogenic to humans (Group 2B),
based on an increased risk for glioma, a malignant type of brain cancer1, associated with
wireless phone use.
Over the last few years, there has been mounting concern about the possibility of adverse
health effects resulting from exposure to radiofrequency electromagnetic fields, such as those
emitted by wireless communication devices. The number of mobile phone subscriptions is
estimated at 5 billion globally.
From May 24–31 2011, a Working Group of 31 scientists from 14 countries has been meeting
at IARC in Lyon, France, to assess the potential carcinogenic hazards from exposure to
radiofrequency electromagnetic fields. These assessments will be published as Volume 102 of
the IARC Monographs, which will be the fifth volume in this series to focus on physical agents,
after Volume 55 (Solar Radiation), Volume 75 and Volume 78 on ionizing radiation (X-rays,
gamma-rays, neutrons, radio-nuclides), and Volume 80 on non-ionizing radiation (extremely
low-frequency electromagnetic fields).
The IARC Monograph Working Group discussed the possibility that these exposures might
induce long-term health effects, in particular an increased risk for cancer. This has relevance for
public health, particularly for users of mobile phones, as the number of users is large and
growing, particularly among young adults and children.
The IARC Monograph Working Group discussed and evaluated the available literature on the
following exposure categories involving radiofrequency electromagnetic fields:
.. occupational exposures to radar and to microwaves;
.. environmental exposures associated with transmission of signals for radio, television and
wireless telecommunication; and
.. personal exposures associated with the use of wireless telephones.
International experts shared the complex task of tackling the exposure data, the studies of
cancer in humans, the studies of cancer in experimental animals, and the mechanistic and
other relevant data.
1 237 913 new cases of brain cancers (all types combined) occurred around the world in 2008 (gliomas represent
2/3 of these). Source: Globocan 2008
2 'Limited evidence of carcinogenicity': A positive association has been observed between exposure to the agent
and cancer for which a causal interpretation is considered by the Working Group to be credible, but chance, bias or
confounding could not be ruled out with reasonable confidence.
3 'Inadequate evidence of carcinogenicity': The available studies are of insufficient quality, consistency or statistical
power to permit a conclusion regarding the presence or absence of a causal association between exposure and
cancer, or no data on cancer in humans are available.
4 a. 'Acoustic neuroma risk in relation to mobile telephone use: results of the INTERPHONE international case-
control study' (the Interphone Study Group, in Cancer Epidemiology, in press)
b. 'Estimation of RF energy absorbed in the brain from mobile phones in the Interphone study' (Cardis et al.,
Occupational and Environmental Medicine, in press)
c. 'Risk of brain tumours in relation to estimated RF dose from mobile phones – results from five Interphone
countries' (Cardis et al., Occupational and Environmental Medicine, in press)
d. 'Location of Gliomas in Relation to Mobile Telephone Use: A Case-Case and Case-Specular Analysis' (American
Journal of Epidemiology, May 24, 2011. [Epub ahead of print].
The evidence was reviewed critically, and overall evaluated as being limited2 among users of
wireless telephones for glioma and acoustic neuroma, and inadequate3 to draw conclusions for
other types of cancers. The evidence from the occupational and environmental exposures
mentioned above was similarly judged inadequate. The Working Group did not quantitate the
risk; however, one study of past cell phone use (up to the year 2004), showed a 40% increased
risk for gliomas in the highest category of heavy users (reported average: 30 minutes per day
over a 10-year period).
Dr Jonathan Samet (University of Southern California, USA), overall Chairman of the Working
Group, indicated that "the evidence, while still accumulating, is strong enough to support a
conclusion and the 2B classification. The conclusion means that there could be some risk, and
therefore we need to keep a close watch for a link between cell phones and cancer risk."
"Given the potential consequences for public health of this classification and findings," said IARC
Director Christopher Wild, "it is important that additional research be conducted into the long-
term, heavy use of mobile phones. Pending the availability of such information, it is important
to take pragmatic measures to reduce exposure such as hands-free devices or texting. "
The Working Group considered hundreds of scientific articles; the complete list will be published
in the Monograph. It is noteworthy to mention that several recent in-press scientific articles4
resulting from the Interphone study were made available to the working group shortly before it
was due to convene, reflecting their acceptance for publication at that time, and were included
in the evaluation.
A concise report summarizing the main conclusions of the IARC Working Group and the
evaluations of the carcinogenic hazard from radiofrequency electromagnetic fields (including
the use of mobile telephones) will be published in The Lancet Oncology in its July 1 issue, and in
a few days online.
For more information, please contact
Dr Kurt Straif, IARC Monographs Section, at +33 472 738 511, or
IARC Monographs Section, at +33 472 738 659, or
Communications Group, at
Link to the audio file posted shortly after the briefing:
The International Agency for Research on Cancer (IARC) is part of the World Health
Organization. Its mission is to coordinate and conduct research on the causes of human cancer,
the mechanisms of carcinogenesis, and to develop scientific strategies for cancer control. The
Agency is involved in both epidemiological and laboratory research and disseminates scientific
information through publications, meetings, courses, and fellowships.
If you wish your name to be removed from our press release e-mailing list, please write to
Nicolas Gaudin, Ph.D.
Head, IARC Communications
International Agency for Research on Cancer
World Health Organization
150, cours Albert-Thomas
ABOUT THE IARC MONOGRAPHS
What are the IARC Monographs?
The IARC Monographs identify environmental factors that can increase the risk of human
cancer. These include chemicals, complex mixtures, occupational exposures, physical and
biological agents, and lifestyle factors. National health agencies use this information as scientific
support for their actions to prevent exposure to potential carcinogens. Interdisciplinary working
groups of expert scientists review the published studies and evaluate the weight of the evidence
that an agent can increase the risk of cancer. The principles, procedures, and scientific criteria
that guide the evaluations are described in the Preamble to the IARC Monographs.
Since 1971, more than 900 agents have been evaluated, of which approximately 400 have been
identified as carcinogenic or potentially carcinogenic to humans.
Group 1: The agent is carcinogenic to humans.
This category is used when there is sufficient evidence of carcinogenicity in humans.
Exceptionally, an agent may be placed in this category when evidence of carcinogenicity in
humans is less than sufficient but there is sufficient evidence of carcinogenicity in experimental
animals and strong evidence in exposed humans that the agent acts through a relevant
mechanism of carcinogenicity.
This category includes agents for which, at one extreme, the degree of evidence of
carcinogenicity in humans is almost sufficient, as well as those for which, at the other extreme,
there are no human data but for which there is evidence of carcinogenicity in experimental
animals. Agents are assigned to either Group 2A (probably carcinogenic to humans) or Group 2B
(possibly carcinogenic to humans) on the basis of epidemiological and experimental evidence of
carcinogenicity and mechanistic and other relevant data. The terms probably carcinogenic and
possibly carcinogenic have no quantitative significance and are used simply as descriptors of
different levels of evidence of human carcinogenicity, with probably carcinogenic signifying a
higher level of evidence than possibly carcinogenic.
Group 2A: The agent is probably carcinogenic to humans.
This category is used when there is limited evidence of carcinogenicity in humans and sufficient
evidence of carcinogenicity in experimental animals. In some cases, an agent may be classified in
this category when there is inadequate evidence of carcinogenicity in humans and sufficient
evidence of carcinogenicity in experimental animals and strong evidence that the carcinogenesis
is mediated by a mechanism that also operates in humans. Exceptionally, an agent may be
classified in this category solely on the basis of limited evidence of carcinogenicity in humans. An
agent may be assigned to this category if it clearly belongs, based on mechanistic
considerations, to a class of agents for which one or more members have been classified in
Group 1 or Group 2A.
Group 2B: The agent is possibly carcinogenic to humans.
This category is used for agents for which there is limited evidence of carcinogenicity in humans
and less than sufficient evidence of carcinogenicity in experimental animals. It may also be used
when there is inadequate evidence of carcinogenicity in humans but there is sufficient evidence
of carcinogenicity in experimental animals. In some instances, an agent for which there is
inadequate evidence of carcinogenicity in humans and less than sufficient evidence of
carcinogenicity in experimental animals together with supporting evidence from mechanistic
and other relevant data may be placed in this group. An agent may be classified in this category
solely on the basis of strong evidence from mechanistic and other relevant data.
Group 3: The agent is not classifiable as to its carcinogenicity to humans.
This category is used most commonly for agents for which the evidence of carcinogenicity is
inadequate in humans and inadequate or limited in experimental animals.
Exceptionally, agents for which the evidence of carcinogenicity is inadequate in humans but
sufficient in experimental animals may be placed in this category when there is strong evidence
that the mechanism of carcinogenicity in experimental animals does not operate in humans.
Agents that do not fall into any other group are also placed in this category.
An evaluation in Group 3 is not a determination of non-carcinogenicity or overall safety. It often
means that further research is needed, especially when exposures are widespread or the cancer
data are consistent with differing interpretations.
Group 4: The agent is probably not carcinogenic to humans.
This category is used for agents for which there is evidence suggesting lack of carcinogenicity in
humans and in experimental animals. In some instances, agents for which there is inadequate
evidence of carcinogenicity in humans but evidence suggesting lack of carcinogenicity in
experimental animals, consistently and strongly supported by a broad range of mechanistic and
other relevant data, may be classified in this group.
Definitions of evidence, as used in IARC Monographs for studies in humans
The evidence relevant to carcinogenicity from studies in humans is classified into one of the
Sufficient evidence of carcinogenicity: The Working Group considers that a causal relationship
has been established between exposure to the agent and human cancer. That is, a positive
relationship has been observed between the exposure and cancer in studies in which chance,
bias and confounding could be ruled out with reasonable confidence. A statement that there is
sufficient evidence is followed by a separate sentence that identifies the target organ(s) or
tissue(s) where an increased risk of cancer was observed in humans. Identification of a specific
target organ or tissue does not preclude the possibility that the agent may cause cancer at other
Limited evidence of carcinogenicity: A positive association has been observed between
exposure to the agent and cancer for which a causal interpretation is considered by the Working
Group to be credible, but chance, bias or confounding could not be ruled out with reasonable
Inadequate evidence of carcinogenicity: The available studies are of insufficient quality,
consistency or statistical power to permit a conclusion regarding the presence or absence of a
causal association between exposure and cancer, or no data on cancer in humans are available.
Evidence suggesting lack of carcinogenicity: There are several adequate studies covering the
full range of levels of exposure that humans are known to encounter, which are mutually
consistent in not showing a positive association between exposure to the agent and any studied
cancer at any observed level of exposure. The results from these studies alone or combined
should have narrow confidence intervals with an upper limit close to the null value (e.g. a
relative risk of 1.0). Bias and confounding should be ruled out with reasonable confidence, and
the studies should have an adequate length of follow-up. A conclusion of evidence suggesting
lack of carcinogenicity is inevitably limited to the cancer sites, conditions and levels of exposure,
and length of observation covered by the available studies. In addition, the possibility of a very
small risk at the levels of exposure studied can never be excluded.
In some instances, the above categories may be used to classify the degree of evidence related
to carcinogenicity in specific organs or tissues.